Chagas disease novel drug targets and treatments PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Chagas disease novel drug targets and treatments PDF full book. Access full book title Chagas disease novel drug targets and treatments by Vilma G. Duschak. Download full books in PDF and EPUB format.
Author: Vilma G. Duschak
Publisher: Frontiers Media SA
ISBN: 2832526748
Category : Science
Languages : en
Pages : 129
Get Book Here
Book Description
Author: Vilma G. Duschak
Publisher: Frontiers Media SA
ISBN: 2832526748
Category : Science
Languages : en
Pages : 129
Get Book Here
Book Description
Author: Jenny Telleria
Publisher: Elsevier
ISBN: 0123848776
Category : Medical
Languages : en
Pages : 871
Get Book Here
Book Description
Chagas disease causes severe socioeconomic impact and a high medical cost in Latin America. WHO and the World Bank consider Chagas disease as the fourth most transmittable disease to have a major impact on public health in Latin America: 120 million persons are potentially exposed, 16 to 18 million of whom are presently infected, causing 45,000 to 50,000 deaths per year. It has been calculated that approximately 2.4 million potential working years are lost because of incapacity and mortality due to the disease, for an annual cost estimated at 20 billion Euros. American Trypanosomiasis provides a comprehensive overview of Chagas disease and discusses the latest discoveries concerning the three elements that compose the transmission chain of the disease: - The host: human and mammalian reservoirs - The insect vectors: domestic and sylvatic vectors - The causative parasite: Trypanosoma cruzi - Informs and updates on all the latest developments in the field - Contributions from leading authorities and industry experts
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9241564865
Category : Medical
Languages : en
Pages : 211
Get Book Here
Book Description
"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.
Author: María-Jesús Pinazo Delgado
Publisher: Springer Nature
ISBN: 3030440540
Category : Medical
Languages : en
Pages : 253
Get Book Here
Book Description
This book provides a comprehensive resource on various aspects of the parasite Trypanosoma cruzi and the neglected tropical disease Chagas disease (American trypanosomiasis), the disorder resulting from infection with the parasite. Topics include the biological description and taxonomy of the parasite, epidemiology and transmission routes, laboratory techniques in use when working with the parasite, as well as diagnostic measures and treatment of Chagas disease. Furthermore, a chapter with life stories of people in contact with the disease in endemic as well as non-endemic countries is included. The book is therefore a valuable source for individuals engaged in basic research as well as patient care and health management related to American trypanosomiasis.
Author: Luis Rivas
Publisher: Royal Society of Chemistry
ISBN: 1788012585
Category : Science
Languages : en
Pages : 422
Get Book Here
Book Description
For human health, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Globally, 10 to 12 million people are infected with 1.5 million new cases every year. The development of cheaper new drugs is urgently needed for this neglected disease that is developing resistance to current treatments. Chemotherapy remains the only treatment option for the bulk of patients. However, this is largely unaffordable for most. In the past three years numerous advances in drug discovery have been made for treating this disease by exploiting diverging metabolic pathways between the Leishmania enzymes and their hosts, using nanotechnology to target the immune cell phagolysosomes where Leishmania resides. Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania. Recent studies have shown that leishmaniasis affects some of the poorest people in the world, with 95% of fatal cases occurring in only 6 countries. With the WHO goal of eliminating this public health problem in the South-east Asia Region by 2020, this book will be important for anyone who is interested in neglected tropical diseases.
Author: K. D. Rainsford
Publisher: Springer Science & Business Media
ISBN: 3764374101
Category : Medical
Languages : en
Pages : 445
Get Book Here
Book Description
Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) which acts as a cyclooxygenase- 2 inhibitor but also has other novel pharmacological features which account for its effect in the control of pain and inflammation. It has become a leading NSAID in over 50 countries worldwide. This book provides a comprehensive and fully up-to-date critical review of the published literature on nimesulide, including comparisons with anti-inflammatory, analgesic and antipyretic agents. The emphasis is on the action of nimesulide in relation to its therapeutic and side effects in comparison with other established NSAIDs, including the new class of Coxibs. The chapters are written by leading experts and cover development of nimesulide, including synthesis and production, introduction, and approved uses and applications, followed by pharmacokinetics and toxicological properties, adverse reactions and their mechanisms.
Author: Venkatesan Jayaprakash
Publisher: CRC Press
ISBN: 1351011634
Category : Medical
Languages : en
Pages : 429
Get Book Here
Book Description
Medicinal Chemistry of Neglected and Tropical Diseases: Advances in the Design and Synthesis of Antimicrobial Agents consolidates and describes modern drug discovery and development approaches currently employed to identify effective chemotherapeutic agents for the treatment of Neglected Tropical Diseases (NTDs) from a medicinal chemistry perspective. Chapters are designed to cater to the needs of medicinal chemists who work with chemotherapeutic developments for NTDs, as well as serve as a guide to budding medicinal chemists who wish to work in this area. It will introduce rational drug design approaches adopted in designing chemotherapeutics and validated targets available for the purpose.
Author: Daisy Hernandez
Publisher: National Geographic Books
ISBN: 1951142527
Category : Social Science
Languages : en
Pages : 0
Get Book Here
Book Description
Growing up in a New Jersey factory town in the 1980s, Daisy Hernández believed that her aunt had become deathly ill from eating an apple. No one in her family, in either the United States or Colombia, spoke of infectious diseases. Even into her thirties, she only knew that her aunt had died of Chagas, a rare and devastating illness that affects the heart and digestive system. But as Hernández dug deeper, she discovered that Chagas—or the kissing bug disease—is more prevalent in the United States than the Zika virus. After her aunt’s death, Hernández began searching for answers. Crisscrossing the country, she interviewed patients, doctors, epidemiologists, and even veterinarians with the Department of Defense. She learned that in the United States more than three hundred thousand people in the Latinx community have Chagas, and that outside of Latin America, this is the only country with the native insects—the “kissing bugs”—that carry the Chagas parasite. Through unsparing, gripping, and humane portraits, Hernández chronicles a story vast in scope and urgent in its implications, exposing how poverty, racism, and public policies have conspired to keep this disease hidden. A riveting and nuanced investigation into racial politics and for-profit healthcare in the United States, The Kissing Bug reveals the intimate history of a marginalized disease and connects us to the lives at the center of it all.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241565516
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
WHO's Global Tuberculosis Report provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in care and prevention at global, regional and country levels. This is done in the context of recommended global TB strategies and associated targets, and broader development goals. For the period 2016-2035, these are WHO's End TB Strategy and the United Nations' (UN) Sustainable Development Goals (SDGs), which share a common aim: to end the global TB epidemic. The main data sources for the report are annual rounds of global TB data collection implemented by WHO's Global TB Program since 1995 and databases maintained by other WHO departments, UNAIDS and the World Bank. In WHO's 2017 round of global TB data collection, 201 countries and territories that account for over 99% of the world's population and TB cases reported data.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241565523
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
The World Malaria Report 2017 presents a comprehensive state of play in global progress in the fight against malaria up to the end of 2016. It tracks progress in investments in malaria programs and research, malaria prevention, diagnosis and treatment, surveillance, trends in malaria disease burden, malaria elimination, and threats in tackling malaria and safeguarding the investments made. The report draws on data from 91 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held by other organizations. This year's report shows that after an unprecedented period of success in global malaria control, progress has stalled. In 2016, there were an estimated 216 million cases of malaria, an increase of about 5 million cases over 2015. Deaths reached 445,000, a similar number to the previous year.
